Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
AssigneeBionaut Pharmaceuticals, Inc.
InventorsMehran Khodadoust, Ajay Sharma
Life of this patent
Estimating the term…
Abstract
The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na+/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for treating pancreatic cancers.
Claims22
A pharmaceutical formulation comprising a Na+/K+-ATPase inhibitor, either alone or in combination with an anti-cancer agent, formulated in a pharmaceutically acceptable excipient and suitable for use in humans to treat pancreatic cancer.
A kit for treating a patient having pancreatic cancer, comprising a Na+/K+-ATPase inhibitor, either alone or in combination with an anti-cancer agent, each formulated in premeasured doses for administration to the patient.
A method for treating a patient having pancreatic cancer, comprising administering to the patient an effective amount of a Na+/K+-ATPase inhibitor, either alone or in combination with an anti-cancer agent.
A method for promoting treatment of a patient having pancreatic cancer, comprising packaging, labeling and/or marketing a Na+/K+-ATPase inhibitor, either alone or in combination with an anti-cancer agent, for use in therapy for treating the patient.
A method for promoting treatment of a patient having pancreatic cancer, comprising packaging, labeling and/or marketing an anti-cancer agent to be used in conjoint therapy with a Na+/K+-ATPase inhibitor for treating the patient.
Dependencies are inferred from the claim text.